EDEL THERAPEUTICS

What EDEL THERAPEUTICS does

EDEL Therapeutics is a Swiss private biotechnology company founded in 1997 and headquartered in Lausanne, Switzerland. According to its public description, the company has assembled a technology platform focused on oxidative stress and DNA oxidative damage — biological mechanisms implicated in aging, neurodegeneration, cancer, and inflammatory disease — implying an early-stage therapeutic R&D orientation targeting cellular damage pathways.

Beyond this thematic positioning, the publicly available information set is sparse. No specific products, drug candidates, pipeline assets, or platform technical specifications are disclosed. The company's primary web property (edeltherapeutics.com) currently displays a default cPanel server-misconfiguration page, indicating either an inactive hosting environment or a lapse in web administration; this is documented No leadership team, partnerships, regulatory milestones, or recent news coverage are present in the input data. The only documented capital event is a 2003 grant of approximately $73,733 from the Swiss Foundation for Innovation and Technology (FIT). The company's stated headcount band of 11-50 employees is not corroborated by any other signal in the data.

The business model cannot be characterized from the input. Given the therapeutic focus and small size, plausible revenue mechanisms — if the company is commercially active — would include out-licensing, research collaborations, or grant funding; however, none are documented. The combination of a 1997 founding date, minimal disclosed capital, absent web presence, and no recent verifiable activity suggests either a dormant entity, a very small consulting/research operation, or a company whose current activities are simply not reflected in available public sources.

Name

EDEL THERAPEUTICS

Website

https://edeltherapeutics.com

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

11–50 employees

Short description

EDEL Therapeutics is a privately held Swiss biotechnology company, founded in 1997 in Lausanne, that has built a technology platform in the field of oxidative stress and DNA oxidative damage, targeting therapeutic applications in cellular damage pathways.

Ownership category

akta.pro rank

Product category

Biopharmaceutical R&D — Oxidative Stress Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

siRNA Therapeutics (gene silencing) (HLAAADAB)

Keywords

• Oxidative stress therapeutics
• DNA damage research
• Biopharmaceutical platform
• Redox biology therapeutics
• Small molecule discovery

Headquarters

HQ city

Lausanne

HQ country

Switzerland

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations

Core offering

EDEL THERAPEUTICS operates as a biopharmaceutical research company that has built a comprehensive technology platform focused on oxidative stress and DNA oxidative damage. Its work targets the mechanistic understanding and therapeutic exploitation of redox biology and oxidative DNA lesions. No commercialized products, pricing, or named pipeline assets are documented in the available source material.

Differentiator

Problem solved

Functional benefit

Products and services

• Oxidative stress and DNA oxidative damage research platform Comprehensive in-house technology platform dedicated to studying oxidative stress and DNA oxidative damage, supporting the company's therapeutic discovery and research activities.

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Expansion highlights1 record

Broad incumbents

• Roche: Roche is a Swiss-headquartered global pharma and diagnostics leader with active DNA-damage-response oncology programs. Most relevant geographically co-located broad incumbent.
• Vertex Pharmaceuticals: Vertex is a large biotech with rare-disease and emerging DNA-damage-response programs. Operates broadly in the same therapeutic space as a well-capitalized comparator.
• Novartis: Swiss-headquartered global pharma with broad programs in oncology and neurology where DNA oxidative damage biology is relevant. Co-located large incumbent with potential BD interest.
• Astellas Pharma: Large Japanese pharma with active programs in DNA damage response and oxidative stress oncology. Broad incumbent exploring the same biology EDEL targets.
• BioMarin Pharmaceutical: BioMarin is a specialty rare-disease biopharma. Relevant as a comparable established mid-cap biotech that scaled a niche therapeutic platform.

Direct peers

• Aclaris Therapeutics: Aclaris Therapeutics develops targeted therapeutics for oxidative stress-driven inflammatory and dermatological conditions. Comparable oxidative-stress focused clinical-stage biotech.
• Inotek Pharmaceuticals: Inotek developed small-molecule therapeutics targeting oxidative stress pathways (notably in glaucoma). Historically comparable oxidative stress specialty biotech.
• BioElectron Technology Corporation: BioElectron developed proprietary oxidative stress-targeted therapeutics for wound healing and ophthalmology. Closely comparable in mechanism and stage to EDEL Therapeutics.
• Astrocyte Pharmaceuticals: Astrocyte Pharmaceuticals develops neuroprotective compounds targeting oxidative stress and astrocyte biology for neurological indications. Comparable niche-stage oxidative stress biotech.
• Aeolus Pharmaceuticals: Aeolus Pharmaceuticals develops small-molecule catalytic antioxidants targeting oxidative stress-related diseases. Directly comparable to EDEL's focus on oxidative stress therapeutics and DNA damage biology.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat1 record

Key risks4 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/edel-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EDEL THERAPEUTICS